Partnership between Central Scientific Commerce and Cytosurge

Within this partnership, CSC now provides to the Japanese market our highly automated and easy to use FluidFM OMNIUM system enabling cutting-edge research in areas such as neuroscience, monoclonal cell line development, virology, mechanobiology, nanoprinting, and single cell omics. We are very proud to have partnered with such a well-experienced industry leader. We look forward to a mutually successful collaboration with CSC and to enabling customers in Japan access to our FluidFM technology.

About Central Scientific Commerce, Inc.

Central Scientific Commerce, Inc., known as “CSC”, was founded in 1967 in Tokyo as a specialized sales organization to import scientific and analytical instruments as well as medical and pharmaceutical products. Currently CSC has 4 offices in Japan, Tokyo, Osaka, Fukuoka and Sapporo, to cover the entire Japanese market. They import products directly from suppliers, or those made for CSC under OEM, to sell them to end users. While CSC deals directly with the end users, they also use about 80 local distributors. CSC maintains all the licenses needed to work in the specific market, and staff to provide technical and engineering support to the users in the fields such as life science research, environmental science, cell and microbiology science and clinical chemistry. In 1979 CSC became a subsidiary of GSI Creos, Inc, a general trading company listed in Tokyo Stock-Exchange Market.

For more information, visit www.cscjp.co.jp. 

About Cytosurge AG

Since 2009, Cytosurge AG develops, manufactures, and distributes state-of-the-art nanotechnology solutions and systems based on its patented FluidFM® technology.

At the heart of the technology are the hollow FluidFM probes, which have apertures down to 300 nm, enabling the handling of femtoliter volumes. With its FluidFM solutions Cytosurge brings significant benefits to a wide range of applications in life sciences. More than 100 labs are already using FluidFM systems and go beyond conventional technological boundaries in CRISPR cell line development, mechanobiology, virology, single cell omics, neuroscience, and nanoprinting.

For more information, visit www.cytosurge.com.